About Us

MABT’s current mission is to develop therapies for Rabies and advanced Flu patients.

MABT was founded in 2011 with the mission of eradicating life-threatening infectious diseases using a transformative, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. This revolutionary type of immune system-based therapy is called “immunotherapy”.

We are a pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively creating a revolutionary treatment paradigm for viral diseases, such as Rabies and advanced Flu.

Rabies represents a unique unmet medical need, for which there is no effective therapy. Rabies is the most lethal organism known to the medical community, with a fatality rate of essentially 100%. In addition, rabies consistently impacts more lives annually than other viruses that are in the news, like Ebola. For example, in the 40-year history of known Ebola infections ~15,000 people have died but, in that same 40-year period, over 3 million people have died from rabies

Press

Click below to see Press Release


Research

IMT504

IMT504 is a novel, patented immunotherapy that has shown robust results in testing 

Immunotherapy

Our approach to combating bacteria and viruses can revolutionize medical care

Rabies

Rabies is the world’s most lethal disease, killing virtually 100% of brain-infected patients

Flu

The Flu kills tens of thousands every year, new therapies for advanced Flu are essential

IMT504 Super Charges your own Immune System

Learn More

Technology

IMT504 is a novel oligodeoxynucleotide immunotherapy that has shown robust results in numerous animal safety and efficacy models, as well as in humans. Recent data suggest that IMT504 will be a highly effective therapy for advanced Coronavirus and flu patients. Additional exciting data suggests that the IMT504 platform could be an effective treatment for other diseases too. 

IMT504 is our proprietary, patented technology platform with over $23 Million invested in research. Our technology platform creates a very rapid, safe and effective immune system response. IMT504 has the ability to address emergency situations like the current COVID-19 pandemic. 


Global Market

Global Anti-Infectives Market

Infectious diseases are one of the leading causes of morbidity and mortality throughout the world. The global market for all infectious diseases is expected to be ~$100 billion dollars by 2022, and is …

Fatality Rates

Rabies represents a unique unmet medical need, for which there is no effective therapy. Rabies is the most lethal organism known to the medical community, with a fatality rate of …

Antibiotic Resistance

Outside the US, over 700,000 deaths are currently attributed to resistant bacteria. However, given recent trends in resistance, these numbers are expected to skyrocket to over 10,000,000 deaths/year by 2050, …

Contact Us

Mid-Atlantic BioTherapeutics

We are always interested in hearing from you! Please fill out a contact us form and hit send. We will reply as soon as possible.

Thank you.



Location

3805 Old Easton Road
Doylestown, PA 18902
USA
info@mabt.us